Affimed N.V. (AFMD)

$0.18 -0.10 (-34.95%)
Market Cap 2.92M
Revenue (ttm) 8.96M
Net Income (ttm) -114.66M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -1,279.69%
Debt to Equity Ratio 0.47
Volume 23,468,002
Avg Vol 19,511,936
Day's Range N/A - N/A
Shares Out 16.10M
Stochastic %K 15%
Beta 2.07
Analysts Sell
Price Target $6.83

Company Profile

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company's lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, wh...

Industry: Biotechnology
Sector: Healthcare
Phone: 49 621 560030
Fax: 49 621 56003 649
Address:
Gottlieb-Daimler-Straße 2, Mannheim, Germany
Hodl707
Hodl707 Mar. 17 at 5:54 PM
$AFMD is it over and done we at 0 !!!
1 · Reply
Hodl707
Hodl707 Mar. 11 at 10:49 AM
$AFMD If you’re Gilde, sitting on Affimed’s RMAT-designated NK cell IP, waiting to house it in Catalym — why would you rush a transaction under the most hostile FDA biologics regulator in recent memory? You wouldn’t. You’d wait. And now Prasad is gone. The regulatory environment just got materially friendlier for exactly this type of novel biologic platform.
0 · Reply
Think_Bigly
Think_Bigly Mar. 8 at 9:59 PM
$AFMD - This is particularly important for R/R HL patients, especially those who are double-refractory, as there are currently no approved therapies for this group.
0 · Reply
Think_Bigly
Think_Bigly Mar. 8 at 9:55 PM
$AFMD I still believe Gilde is in control of the float.. and paying minimal operating costs in order to maintain key trials. Why? The probability of $B FCF is very high. - Key Implications of RMAT The RMAT designation is a significant regulatory milestone that provides several benefits to accelerate the therapy's development: Enhanced FDA Interaction: It allows for more frequent and earlier meetings with the FDA to discuss development plans and potential surrogate endpoints. Expedited Pathways: It opens the door for potential accelerated approval and priority review of a future Biologics License Application (BLA)... contd..
0 · Reply
Think_Bigly
Think_Bigly Mar. 7 at 8:34 PM
$AFMD ... Roche contd.. - The partnership continues to explore other candidates, including AFM24, a tetravalent bispecific engaging NK cells, in combination with Roche’s Tecentriq (atezolizumab), with a Phase 1/2a trial ongoing. Thus, while specific assets have been discontinued, the overall alliance between Roche and Affimed is still operational.
0 · Reply
Think_Bigly
Think_Bigly Mar. 7 at 8:32 PM
$AFMD from Brave AI .. -Roche has not terminated its partnership with Affimed, but it has discontinued certain development programs under their collaboration. In July 2021, Roche announced the discontinuation of RG6296 (AFM26), a bispecific antibody targeting BCMA for multiple myeloma, developed under the Affimed collaboration. This decision was driven by intense competition in the BCMA space, with advanced CAR-T therapies and other bispecifics demonstrating strong efficacy. Despite Affimed’s promising NK cell-engaging platform, the project was halted due to the high bar for differentiation in this therapeutic area. Roche also discontinued two gene therapy programs licensed from 4D Molecular (4D-110 and 4D-125) due to a "change in risk-benefit profile," which affected the broader ophthalmology gene therapy landscape. However, the core strategic collaboration between Roche (via Genentech) and Affimed remains active.
0 · Reply
Hodl707
Hodl707 Mar. 6 at 5:09 AM
$AFMD
0 · Reply
Think_Bigly
Think_Bigly Mar. 6 at 2:28 AM
$AFMD I still think Gilde bought the sh*t out of this 5/16 - 5/19 of 2025.
1 · Reply
Hodl707
Hodl707 Mar. 6 at 1:11 AM
$AFMD one fact stands if this was a normal liquidation, the NV parent would have been disabled by now !! gilde healthcare still shows its portfolio why the site has been updated not NV but Gilde site so you can’t tell me they forgot about it !!
0 · Reply
deathknight
deathknight Mar. 5 at 6:41 PM
$AFMD folks, Claude from Anthropic is simply amazing! I feed it a few publicly available facts: Gilde anchored 2022 offering and bought 6% of common shares; $AFMD stopped doing ATM ever since (they did ATM every year before that) and the company rather layoff R&D staffs and its CEO without tapping ATM; Gilde keeps those shares instead of dumping prior/after insolvency -- unlike all other intuitional investors. Claude independently "deduced" that the most likely reason for Gilde is to conduct a reverse merger with one of its portfolio companies. I then asked if Catalym is a good fit for the merger and Claude not only aligned both companies scientifically (assuming $AFMD keeps some IPs after the proceeding); it also did more corroborative thinking and pointed to me that a recent CFO appointment at Catalym could be a sign of this reverse merger. Surely no one knows the future and Claude can be wrong but it thought process is so impressive -- it's the best IMO.
2 · Reply
Latest News on AFMD
No data available.
Hodl707
Hodl707 Mar. 17 at 5:54 PM
$AFMD is it over and done we at 0 !!!
1 · Reply
Hodl707
Hodl707 Mar. 11 at 10:49 AM
$AFMD If you’re Gilde, sitting on Affimed’s RMAT-designated NK cell IP, waiting to house it in Catalym — why would you rush a transaction under the most hostile FDA biologics regulator in recent memory? You wouldn’t. You’d wait. And now Prasad is gone. The regulatory environment just got materially friendlier for exactly this type of novel biologic platform.
0 · Reply
Think_Bigly
Think_Bigly Mar. 8 at 9:59 PM
$AFMD - This is particularly important for R/R HL patients, especially those who are double-refractory, as there are currently no approved therapies for this group.
0 · Reply
Think_Bigly
Think_Bigly Mar. 8 at 9:55 PM
$AFMD I still believe Gilde is in control of the float.. and paying minimal operating costs in order to maintain key trials. Why? The probability of $B FCF is very high. - Key Implications of RMAT The RMAT designation is a significant regulatory milestone that provides several benefits to accelerate the therapy's development: Enhanced FDA Interaction: It allows for more frequent and earlier meetings with the FDA to discuss development plans and potential surrogate endpoints. Expedited Pathways: It opens the door for potential accelerated approval and priority review of a future Biologics License Application (BLA)... contd..
0 · Reply
Think_Bigly
Think_Bigly Mar. 7 at 8:34 PM
$AFMD ... Roche contd.. - The partnership continues to explore other candidates, including AFM24, a tetravalent bispecific engaging NK cells, in combination with Roche’s Tecentriq (atezolizumab), with a Phase 1/2a trial ongoing. Thus, while specific assets have been discontinued, the overall alliance between Roche and Affimed is still operational.
0 · Reply
Think_Bigly
Think_Bigly Mar. 7 at 8:32 PM
$AFMD from Brave AI .. -Roche has not terminated its partnership with Affimed, but it has discontinued certain development programs under their collaboration. In July 2021, Roche announced the discontinuation of RG6296 (AFM26), a bispecific antibody targeting BCMA for multiple myeloma, developed under the Affimed collaboration. This decision was driven by intense competition in the BCMA space, with advanced CAR-T therapies and other bispecifics demonstrating strong efficacy. Despite Affimed’s promising NK cell-engaging platform, the project was halted due to the high bar for differentiation in this therapeutic area. Roche also discontinued two gene therapy programs licensed from 4D Molecular (4D-110 and 4D-125) due to a "change in risk-benefit profile," which affected the broader ophthalmology gene therapy landscape. However, the core strategic collaboration between Roche (via Genentech) and Affimed remains active.
0 · Reply
Hodl707
Hodl707 Mar. 6 at 5:09 AM
$AFMD
0 · Reply
Think_Bigly
Think_Bigly Mar. 6 at 2:28 AM
$AFMD I still think Gilde bought the sh*t out of this 5/16 - 5/19 of 2025.
1 · Reply
Hodl707
Hodl707 Mar. 6 at 1:11 AM
$AFMD one fact stands if this was a normal liquidation, the NV parent would have been disabled by now !! gilde healthcare still shows its portfolio why the site has been updated not NV but Gilde site so you can’t tell me they forgot about it !!
0 · Reply
deathknight
deathknight Mar. 5 at 6:41 PM
$AFMD folks, Claude from Anthropic is simply amazing! I feed it a few publicly available facts: Gilde anchored 2022 offering and bought 6% of common shares; $AFMD stopped doing ATM ever since (they did ATM every year before that) and the company rather layoff R&D staffs and its CEO without tapping ATM; Gilde keeps those shares instead of dumping prior/after insolvency -- unlike all other intuitional investors. Claude independently "deduced" that the most likely reason for Gilde is to conduct a reverse merger with one of its portfolio companies. I then asked if Catalym is a good fit for the merger and Claude not only aligned both companies scientifically (assuming $AFMD keeps some IPs after the proceeding); it also did more corroborative thinking and pointed to me that a recent CFO appointment at Catalym could be a sign of this reverse merger. Surely no one knows the future and Claude can be wrong but it thought process is so impressive -- it's the best IMO.
2 · Reply
Hodl707
Hodl707 Mar. 3 at 12:16 AM
$AFMD I mean what’s left no info nothing won’t close my position till end of year that’s all !!
0 · Reply
deathknight
deathknight Feb. 27 at 4:54 PM
$AFMD This is why I firmly believe Grok is the worst AI bot out there. All Affimed's clinical trials had been terminated last June/July, including Acimtimag/AB101 combo -- the one with RMAT designation (https://clinicaltrials.gov/study/NCT05883449?intr=AFm13&rank=5&tab=results). It's public information and super easy to verify but Grok still messed up. Totally untrustworthy and useless.
1 · Reply
Think_Bigly
Think_Bigly Feb. 27 at 3:26 AM
$AFMD - Another distinct possibility. -grok:- Acimtimag Early Approval- Overall, with RMAT and Fast Track, strong early efficacy (high ORR/CR in heavily pretreated patients), and favorable safety, the regimen has a promising accelerated approval pathway if expansion cohorts or further data confirm these results. Full approval would likely follow Phase 3 validation. The study remains ongoing (as of recent updates in 2025), with no approval granted yet. Continued enrollment and updated results will be key.
1 · Reply
Think_Bigly
Think_Bigly Feb. 25 at 4:36 AM
Huge future cash flow...​ $AFMD >> $ARTV >> Roche
0 · Reply
Think_Bigly
Think_Bigly Feb. 19 at 10:02 PM
$AFMD still listed.. https://gildehealthcare.com/portfolio/venture-and-growth/affimed/
0 · Reply
Think_Bigly
Think_Bigly Feb. 19 at 9:40 PM
$AFMD - grok Recapitalization (60%): Highest likelihood—fits distressed restructurings where existing stakeholders inject funds to stabilize and advance acimtamig toward Phase 3. RMAT reduces regulatory risk, making it fundable (~50-70% success rate for RMAT therapies reaching approval). Pre-insolvency cash was ~€10M (Q3 2024), so a €20-50M round could extend runway to 2027 data readouts. Buyout (30%): Reasonable for a full acquisition, especially if a suitor values the IP/pipeline at $100-200M EV (based on RMAT precedents; e.g., similar IO assets traded at 2-3x peak cash in 2024 deals). No direct rumors, but 2024's 1,078 biotech M&As show appetite for late-stage oncology.
0 · Reply
deathknight
deathknight Feb. 19 at 5:30 PM
$AFMD holding this stock is like sitting inside a dark space capsule without knowing the time, the location and what to expect. When the door finally opens -- if can be opened at all, would it be an barren apocalypse world outside? Or a Eden garden? Will there be beautiful starry light and moons or just thick toxic clouds. The good part of the journey is the unknown but this is also the worst part.
0 · Reply
Hodl707
Hodl707 Feb. 18 at 7:41 PM
$AFMD https://www.dcfmodeling.com/blogs/history/afmd-history-mission-ownership
0 · Reply
Think_Bigly
Think_Bigly Feb. 14 at 9:29 PM
$AFMD AFMD-my thoughts. Roche deal shows their high level of interest, with $4.9B in up front and milestones, 3rd largest ever. They know more than any one that with ROCK platform, AFM-13 P2 Acimitag results, and indications coming from AFM-24 + AFM-28, there is significant value for them. An offer of 5-10% of that original would establish full control of the platform for their benefit. An accomplished insolvency administrater would understand that and inform & educate the court. Roche' task is to now look the judge in the face and state that there is no further value, AFTER superb results have been acheived across the board. -grok
1 · Reply
Think_Bigly
Think_Bigly Feb. 12 at 3:15 AM
$AFMD the subsidiary's (Affimed GmbH) insolvency proceedings have not closed yet. As of February 11, 2026, public records and company updates indicate it remains in liquidation - grok
0 · Reply
deathknight
deathknight Feb. 9 at 9:21 PM
$AFMD In light of this most recent announcement, if the subsidiary's proceeding hasn't closed yet (no money flowed to the parent through its ownership), this would be a huge positive sign as the Bootstrap loan is likely made in full by existing cash/inventory and the inter-company loan that the parent lent to its own subsidiary. On the other hand, if the subsidary's proceeding has completed (without announcement), then the shareholders (us and Gilde Healthcare) will likely be wiped out. Can go either way -- just like before.
0 · Reply
deathknight
deathknight Feb. 9 at 8:44 PM
$AFMD The newest court announcement published today: "On February 6, 2026, the insolvency administrator notified the court pursuant to Section 208 of the German Insolvency Code (InsO) that the estate is not expected to be sufficient to fully satisfy the other existing liabilities of the estate when they become due." Not something I hope to see but it is what it is. I am curious about those "other liabilities" that are not due yet. I guess at least current estate can fully satisfy Bootstrap (aka the bank) as their loan was due last November.
1 · Reply